ReproCELLReproCELL Incorporated4978東証グロース化学FY ending Mar 2026, consolidated, J-GAAP
Revenue by business segment, and the profit each one keeps.
Geographic revenue reported in annual filings
No geographic revenue breakdown was disclosed.
※ Segment figures include inter-segment sales and do not sum to the company total
X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.
Bubble size represents latest revenue. Segments without a CAGR are placed at the left edge; their horizontal position is not a growth value. Color indicates positive or negative margin.
| Segment | Revenue CAGR | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|---|
| Research Support Business | +10.2%5y | 1,3819.8% | 2,01818.2% | 2,08021.4% | 2,41525.7% | 1,9524.9% |
| Medical Business | +26.7%5y | 854-7.4% | 9366.0% | 34763.5% | 56428.1% | 281-15.6% |
Top: revenue. Bottom: operating margin.
EDINET (FSA Japan)
有価証券報告書－第24期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第23期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第22期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第21期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第20期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第19期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 42 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.